Difference between revisions of "Interferon alfa-n1 (Wellferon)"
Jump to navigation
Jump to search
m |
m |
||
| Line 15: | Line 15: | ||
[[Category:Subcutaneous medications]] | [[Category:Subcutaneous medications]] | ||
| − | [[Category: | + | [[Category:Interferon alfas]] |
[[Category:Chronic myeloid leukemia medications]] | [[Category:Chronic myeloid leukemia medications]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 14:11, 1 August 2023
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
Also known as
- Brand name: Wellferon